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A 26-year-old gravida 1, para 0, woman was referred to
the hospital at 18 weeks of gestation for evaluation of
trisomy 13 mosaicism. She had undergone amniocen-
tesis at 16 weeks of gestation because of an abnormal
result in maternal serum screening for Down syndrome.
Among 16 colonies of amniocytes, five had a karyotype
of 47,XY,+13 and 11 had a karyotype of 46,XY, and the
karyotype was 47,XY,+13[5]/46,XY[11]. Level II ultra-
sound showed no structural abnormalities. Repeated
amniocentesis at 19 weeks of gestation revealed a kary-
otype of 47,XY,+13[3]/46,XY[17]. Among 20 colonies
of amniocytes, three had a karyotype of 47,XY, +13 and
17 had a karyotype of 46,XY. The woman subsequently
elected to terminate the pregnancy. A male fetus was
delivered with no demonstrable gross abnormalities.
DNA was isolated from the uncultured tissues of
cord blood, umbilical cord and placenta. Quantitative
fluorescent polymerase chain reaction (QF-PCR) assays
and polymorphic short tandem repeat markers for
chromosome 13 were used for determination of aneu-
ploidy and the parental origin of the extra chromosome
(Table, Figure). Complete trisomy 13 was evident in the
tissue of placenta. The specimen of placenta showed 
a diallelic pattern with a dosage ratio of 1:2 (paternal
allele: maternal allele) for the chromosome 13-specific
markers. The specimen of placenta showed one copy of
a paternal allele and two copies of a single maternal
allele in chromosome 13. The specimens of cord blood
and umbilical cord showed a diallelic pattern with a
dosage ratio of 1:1.3 (paternal allele to maternal allele
ratio) and 1:1.2 (paternal allele to maternal allele
ratio), respectively, for the chromosome 13-specific
markers.
We have presented the clinical and molecular find-
ings of prenatally diagnosed mosaic trisomy 13. Our
presentation shows the usefulness of QF-PCR in the
rapid tissue confirmation of mosaic trisomy 13 in the
fetal tissues and trisomy 13 in placental tissue. Trisomy
13 mosaicism in the fetal tissues in this case was most
likely the result of partial trisomic zygote rescue of a
meiosis II nondisjunction error of maternal origin or
possibly a postzygotic mitotic error.
Trisomy 13 or Patau syndrome occurs in 0.5–1 per
10,000 births [1]. Magenis et al [2] proposed that 
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Figure. Representative electrophoretogram of quantitative
fluorescent polymerase chain reaction assays at short tandem
repeat markers for chromosome 13 using parental blood, cord
blood, umbilical cord, and placenta. With the microsatellite
marker D13S789, one paternally originated 164-base pair (bp)
allele and one maternally originated 176-bp allele are seen in
cord blood, umbilical cord and placenta. The two peaks
(164:176 bp) of unequal fluorescent activity with a ratio of 1:2
in the placenta, 1:1.3 in the cord blood and 1:1.2 in the
umbilical cord indicate a maternal origin of mosaic trisomy 13.
trisomy 13 mosaicism occurs in only 5% of all trisomy
13 cases. Trisomy 13 mosaicism is very unusual and
has rarely been recognized at amniocentesis. In a study
of chromosomal mosaicism in 22,000 amniocenteses,
Hsu et al [3] found true chromosomal mosaicism in
0.23% (50/22,000) of the cases, including only two
cases of trisomy 13 mosaicism among the 50 cases of
true chromosomal mosaicism. Patients with complete
trisomy 13 usually manifest early death, severe mental
retardation, and characteristic structural abnormalities
such as holoprosencephaly, Dandy-Walker complex,
congenital heart defects, facial cleft, nuchal edema,
cystic hygroma, scalp defects, omphalocele, urinary tract
abnormalities, and polydactyly. However, patients with
mosaic trisomy 13 most often have longer survival and 
a less severe phenotype, with a wide variation from
essentially normal to grossly abnormal, according to
the tissue distribution of trisomy 13 cells [4–6].
Counseling parents of a child with trisomy 13
mosaicism remains difficult because of phenotypic
variability seen in trisomy 13 mosaicism, with some
patients having a typical phenotype of complete trisomy
13 with neonatal death, and others having few dys-
morphic features with prolonged survival [7]. In a lit-
erature review of 49 published cases with trisomy 13
mosaicism, Griffith et al [7] found that six reported
cases had normal development and intellect, and the
common associated anomalies in other cases with
phenotypic abnormalities were ear anomalies, cleft lip
and palate, and congenital heart defects. The present
case had about 30% of abnormal trisomy 13 cells in the
cord blood but manifested no phenotypic abnormali-
ties. Although the present case was not associated with
characteristic structural abnormalities, the intellectual
condition of this case could not be determined. Griffith
et al [7] suggested that there is no clear correlation
between the percentage of trisomy 13 cells and the 
level of intellectual function in patients with trisomy 
13 mosaicism. This information should be included in
parental counseling during prenatal diagnosis of a low
level of mosaicism for trisomy 13 with no sonographi-
cally demonstrable structural abnormalities.
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Table. Genotypic information of the fetus, extraembryonic tissues and the parents at short tandem repeat (STR) markers 
specific for chromosome 13 by quantitative fluorescent polymerase chain reaction assays*
STRs Locus Father Mother Proband Position (base pair)
D13S789 13q22.3 164,172 175,176 164,176† 77646678–77646835
D13S1809 13q33.2 178,200 200,200 178,200† 104930755–104930944
D13S797 13q33.2 187,207 207,207 187,207† 104930779–104930974
D13S766 13q33.2 135,143 127,135 127,135† 105701369–105701493
D13S248 13q33.3 209,209 235,235 209,235† 106418051–106418252
D13S796 13q33.3 165,165 169,169 165,169† 106686966–106687128
D13S1354 13q34 192,192 192,192 192,192 109230600–109230780
*Alleles (base pair sizes) are listed below each individual; †partial dosage increase approximately 100%, 30% and 20% in placenta, cord blood and umbilical
cord, respectively.
